Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


FORM 8-K

 


Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

October 11, 2007

 


CORTEX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware   1-16467   33-0303583

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(I.R.S Employer

Identification No.)

 

15241 Barranca Parkway

Irvine, California

  92618
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (949) 727-3157

N/A

(Former name or former address, if changed since last report.)

 


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 7.01 Regulation FD Disclosure.

On October 11, 2007, Cortex Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that, on October 10, 2007, the United States Food and Drug Administration (the “FDA”) informed the Company that the FDA would soon be sending formal notice that it would not approve the Company’s Investigational New Drug Application for a Phase IIb study of CX717 in attention deficit hyperactivity disorder. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1

   Press release of Cortex Pharmaceuticals, Inc., dated October 11, 2007.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CORTEX PHARMACEUTICALS, INC.

Date: October 12, 2007

  By:  

/s/ Maria S. Messinger

    Maria S. Messinger
    Vice President, Chief Financial Officer and Corporate Secretary


EXHIBIT INDEX

 

Exhibit
Number
 

Description

 

Sequential

Page No.

99.1   Press release of Cortex Pharmaceuticals, Inc., dated October 11, 2007.   5